 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

- Partial spin-off of Bentrio completed to increase focus on RNA delivery activities - Retains 49% in Altamira Medica AG, and secures 25% of future licensing revenue HAMILTON, BERMUDA, Nov. 29...

Altamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Altamira Therapeutics announces partial spin-off of Bentrio business

Initiates Strategic Repositioning to Focus on Company's Core RNA Delivery Technology Altamira Therapeutics retains 49% in Altamira Medica AG, and secures 25% of future licensing revenue...

Altamira Therapeutics Announces Partial Spin-Off of Bentrio  Business

Hamilton, Bermuda, Nov. 10, 2023 (GLOBE NEWSWIRE) -- November 10, 2023 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing...

Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal Betahistine

HAMILTON, BERMUDA , Sept. 14, 2023 (GLOBE NEWSWIRE) -- Fresh data from randomized controlled NASAR clinical trial further demonstrate efficacy and tolerability of Bentrio nasal spray in...

Altamira Therapeutics Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic Rhinitis

Altamira Therapeutics reports 1H of 2023 revenue CHF 0.1M vs CHF0.3M last year

HAMILTON, BERMUDA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Company hosts 1H 2023 Financial Results and Business Update call today at 8 a.m. ET First research collaboration with biopharmaceutical...

Altamira Therapeutics Provides Business Update and First Half 2023 Financial Results

Altamira Therapeutics Ltd. (CYTO) Q2 2023 Earnings Call Transcript...

Altamira Therapeutics Ltd. (CYTO) Q2 2023 Earnings Call Transcript

HAMILTON, BERMUDA , Sept. 06, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important...

Altamira Therapeutics to Host First Half 2023 Financial Results and Business Update Call on September 12th

HAMILTON, BERMUDA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that its founder, Chairman, and CEO Thomas Meyer will be presenting...

Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global  Investment Conference September 11-13

Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through the Switzerland and Australia geographical segments. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.

Watchers	27,413
52-Wk Low	$0.094
52-Wk High	$5.99

Market Cap	$2.82M
Volume (M)	142,451.00
52-Wk High	$5.99
52-Wk Low	$0.094

CYTO Altamira Therapeutics Ltd

About

Feed

News

Earnings

Fundamentals